Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Neuralstem (CUR) Competitors

Neuralstem logo

CUR vs. CLDI, NKGN, SRNE, SQZ, GNCAQ, GNCA, ELOX, PRME, PLX, and IKT

Should you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include Calidi Biotherapeutics (CLDI), NKGen Biotech (NKGN), Sorrento Therapeutics (SRNE), SQZ Biotechnologies (SQZ), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Eloxx Pharmaceuticals (ELOX), Prime Medicine (PRME), Protalix BioTherapeutics (PLX), and Inhibikase Therapeutics (IKT). These companies are all part of the "medical" sector.

Neuralstem vs. Its Competitors

Neuralstem (NASDAQ:CUR) and Calidi Biotherapeutics (NYSEAMERICAN:CLDI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

38.3% of Neuralstem shares are held by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are held by institutional investors. 5.4% of Neuralstem shares are held by insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neuralstem has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.

In the previous week, Neuralstem's average media sentiment score of 0.00 equaled Calidi Biotherapeutics'average media sentiment score.

Company Overall Sentiment
Neuralstem Neutral
Calidi Biotherapeutics Neutral

Calidi Biotherapeutics has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. Neuralstem's return on equity of -170.51% beat Calidi Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neuralstem-39,417.64% -170.51% -110.16%
Calidi Biotherapeutics N/A -5,152.88%-175.92%

Neuralstem has higher revenue and earnings than Calidi Biotherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuralstem$260K16.15-$4.93MN/AN/A
Calidi Biotherapeutics$50K111.82-$22.14MN/AN/A

Summary

Neuralstem beats Calidi Biotherapeutics on 6 of the 9 factors compared between the two stocks.

Get Neuralstem News Delivered to You Automatically

Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CUR vs. The Competition

MetricNeuralstemBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ Exchange
Market Cap$4.20M$351.16M$6.05B$10.30B
Dividend YieldN/AN/A5.73%4.82%
P/E RatioN/AN/A85.3127.10
Price / Sales16.15489.32601.46133.29
Price / CashN/A22.4425.7730.18
Price / Book0.303.8012.676.69
Net Income-$4.93M-$133.30M$3.32B$276.55M

Neuralstem Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CUR
Neuralstem
N/A$2.00
-4.8%
N/A-41.3%$4.20M$260K0.006High Trading Volume
CLDI
Calidi Biotherapeutics
N/A$1.63
+7.2%
N/AN/A$5.58MN/A0.0038
NKGN
NKGen Biotech
0.1324 of 5 stars
$0.11
flat
N/A-99.3%$4.94MN/A-0.02N/A
SRNE
Sorrento Therapeutics
0.8738 of 5 stars
$0.00
flat
N/A+71.4%$1.93M$60.32M0.00800High Trading Volume
SQZ
SQZ Biotechnologies
N/A$0.03
flat
N/A+10.9%$826K$18.16M-0.011,620Gap Up
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$6KN/A0.0070
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91M0.0070
ELOX
Eloxx Pharmaceuticals
N/A$0.00
flat
N/AN/A$0.00N/A0.0030
PRME
Prime Medicine
3.4834 of 5 stars
$5.59
+0.9%
$8.92
+59.5%
+56.0%$752.27M$4.96M-2.73234Gap Up
PLX
Protalix BioTherapeutics
1.8778 of 5 stars
$2.36
+6.3%
$15.00
+535.6%
+118.5%$177.01M$61.95M-18.15200Positive News
IKT
Inhibikase Therapeutics
1.2653 of 5 stars
$1.61
-0.6%
$6.50
+303.7%
+9.5%$119.97MN/A-0.606

Related Companies and Tools


This page (NASDAQ:CUR) was last updated on 10/13/2025 by MarketBeat.com Staff
From Our Partners